Spyridon Sideromenos

Spyridon Sideromenos

Auto-generated profile, based on publicly available information

Spyridon Sideromenos

Department of Molecular Neurosciences, Center for Brain Research, Medical University of Vienna

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MNMarco Niello
Marco Niello
SSSpyridon Sideromenos
Spyridon Sideromenos
RGRalph Gradisch
Ralph Gradisch
RORonan O´shea
Ronan O´shea
JSJakob Schwazer
Jakob Schwazer
HSHarald H. Sitte
Harald H. Sitte
Psychostimulants interacting with the dopamine transporter (DAT) can be used illicitly or for the treatment of specific neuropsychiatric disorders. However, they can also produce severe and persistent adverse events. Often, their pharmacological properties in vitro do not fully correlate to their pharmacological profile in vivo. Here, we investigated the pharmacological effects of enantiomers of pyrovalerone, α-pyrrolidinovalerophenone, and 3,4-methylenedioxypyrovalerone as compared to the traditional psychostimulants cocaine and methylphenidate, using a variety of in vitro, computational, and in vivo approaches. We found that in vitro drug-binding kinetics at DAT correlate with the time-course of in vivo psychostimulant action in mice. In particular, a slow dissociation (i.e., slowkoff) ofS-enantiomers of pyrovalerone analogs from DAT predicts their more persistent in vivo effects when compared to cocaine and methylphenidate. Overall, our findings highlight the critical importance of drug-binding kinetics at DAT for determining the in vivo profile of effects produced by psychostimulant drugs.

1 September 2022 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SSSpyridon Sideromenos
Spyridon Sideromenos
AGAnna Gundacker
Anna Gundacker
MNMaria Nikou
Maria Nikou
RORaimund Oberle
Raimund Oberle
OHOrsolya Horvath
Orsolya Horvath
DPDaniela D. Pollak
Daniela D. Pollak
A strong bidirectional link between metabolic and psychiatric disorders exists; yet, the molecular basis underlying this interaction remains unresolved. Here we explored the role of the brown adipose tissue (BAT) as modulatory interface, focusing on the involvement of uncoupling protein 1 (UCP-1), a key metabolic regulator highly expressed in BAT, in the control of emotional behavior. Male and female constitutive UCP-1 knock-out (KO) mice were used to investigate the consequences of UCP-1 deficiency on anxiety-related and depression-related behaviors under mild thermogenic (23°C) and thermoneutral (29°C) conditions. UCP-1 KO mice displayed a selective enhancement of anxiety-related behavior exclusively under thermogenic conditions, but not at thermoneutrality. Neural and endocrine stress mediators were not affected in UCP-1 KO mice, which showed an activation of the integrated stress response alongside enhanced fibroblast-growth factor-21 (FGF-21) levels. However, viral-mediated overexpression of FGF-21 did not phenocopy the behavioral alterations of UCP-1 KO mice and blocking FGF-21 activity did not rescue the anxiogenic phenotype of UCP-1 KO mice. No effects of surgical removal of the intrascapular BAT on anxiety-like behavior or FGF-21 levels were observed in either UCP-1 KO or WT mice. We provide evidence for a novel role of UCP-1 in the regulation of emotions that manifests as inhibitory constraint on anxiety-related behavior, exclusively under thermogenic conditions. We propose this function of UCP-1 to be independent of its activity in the BAT and likely mediated through a central role of UCP-1 in brain regions with converging involvement in energy and emotional control. SIGNIFICANCE STATEMENT In this first description of a temperature-dependent phenotype of emotional behavior, we propose uncoupling protein-1 (UCP-1), the key component of the thermogenic function of the brown adipose tissue, as molecular break controlling anxiety-related behavior in mice. We suggest the involvement of UCP-1 in fear regulation to be mediated through its expression in brain regions with converging roles in energy and emotional control. These data are important and relevant in light of the largely unexplored bidirectional link between metabolic and psychiatric disorders, which has the potential for providing insight into novel therapeutic strategies for the management of both conditions.

1 December 2022 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
SSSpyros Sideromenos
Spyros Sideromenos
MNMaria Nikou
Maria Nikou
BCBarbara Czuczu
Barbara Czuczu
NTNikolas Thalheimer
Nikolas Thalheimer
AGAnna Gundacker
Anna Gundacker
DPDaniela D. Pollak
Daniela D. Pollak
Epidemiological studies indicate a bidirectional association between metabolic disturbances, including obesity and related pathological states, and mood disorders, most prominently major depression. However, the biological mechanisms mediating the comorbid relationship between the deranged metabolic and mood states remain incompletely understood. Here, we tested the hypothesis that the enhanced activation of brown fat tissue (BAT), known to beneficially regulate obesity and accompanying dysfunctional metabolic states, is also paralleled by an alteration of affective behaviour. We used upstream stimulatory factor 1 (USF-1) knock-out (KO) mice as a genetic model of constitutively activated BAT and positive cardiometabolic traits and found a reduction of depression-like and anxiety-like behaviours associated with USF-1 deficiency. Surgical removal of interscapular BAT did not impact the behavioural phenotype of USF-1 KO mice. Further, the absence of USF-1 did not lead to alterations of adult hippocampal neural progenitor cell proliferation, differentiation, or survival. RNA-seq analysis characterised the molecular signature of USF-1 deficiency in the hippocampus and revealed a significant increase in the expression of several members of the X-linked lymphocyte-regulated (xlr) genes, including xlr3b and xlr4b. Xlr genes are the mouse orthologues of the human FAM9 gene family and are implicated in the regulation of dendritic branching, dendritic spine number and morphology. The transcriptional changes were associated with morphological alterations in hippocampal neurons, manifested in reduced dendritic length and complexity in USF-1 KO mice. Collectively these data suggest that the metabolic regulator USF-1 is involved in the control of affective behaviour in mice and that this modulation of mood states is unrelated to USF-1-dependent BAT activation, but reflected in structural changes in the brain.

2 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
LGLaurent Gueissaz
Laurent Gueissaz
SSSpyros Sideromenos
Spyros Sideromenos
ETEvgenii O Tretiakov
Evgenii O Tretiakov
RSROBERT SCHNELL
ROBERT SCHNELL
THTibor Harkany
Tibor Harkany
Augmentor α ( Fam150b ) action on the ALK receptor ( Alk ) has gained significance as a hypothalamic signaling pathway with relevance to the control of food intake and energy homeostasis. In contrast, much less is known about the sensitivity of Fam150b - Alk expression and signaling upon noxious challenges. In this regard, acute stress is of particular interest because augmentor α, released from afferents of the food intake circuit of the arcuate hypothalamus in the paraventricular hypothalamus (PVN), could link stress-induced changes in food consumption. Nevertheless, conflicting data exist on whether Fam150b mRNA is expressed in the PVN. Here, we combined single-cell RNA-seq and multiplexed in situ hybridization to demonstrate that both Fam150b and Alk are expressed in the PVN of adult mice, including corticotropin-releasing hormone (CRH)-containing neurons. As such, a dichotomy of CRH neurons is present through their mutually exclusive expression of either Fam150b or Scgn (secretagogin). Fam150b and Alk were not co-expressed. When inducing inflammation-associated stress, Fam150b but not Alk mRNA expression increased in a mifepristone-sensitive manner, implying regulation by peripheral glucocorticoid feedback. We suggest that augmentor α-ALK signaling could underpin, at least partly, stress-induced changes in feeding and the control of body weight.